Severe asthma: start biologics earlier, not as a last resort

Design

Multinational real-world registry cohort study

Population

9,241 patients with severe asthma across 26 countries

Primary outcome

Clinical remission and other outcomes by time to biologic initiation

Effect

Lower remission odds with longer delay (e.g. 0.86 per 10 years of prior asthma)

Biologics for severe asthma are usually held back until standard treatments have failed over years. This analysis of 9,241 patients from three large registries across 26 countries asked whether that delay costs patients.

It appears to. The longer biologics were delayed, the lower the odds of good outcomes afterwards. The odds of clinical remission at 12 months fell for every additional 10 years of pre-biologic asthma, and fell sharply with greater pre-biologic lung-function impairment and higher lifetime oral corticosteroid exposure. Longer delay also tracked with more exacerbations and less lung-function recovery after starting.

The authors frame it as moving from a reserve approach to a preserve approach. The practical message is to consider biologics earlier in severe asthma, before fixed lung-function loss and heavy steroid exposure accumulate, rather than treating them as a final option. This is observational, so it signals a change in timing to weigh, not a mandate.

• Registry analysis of 9,241 severe-asthma patients across 26 countries.
• Longer delay to biologics was associated with lower odds of later remission.
• Remission odds fell with greater pre-biologic lung-function impairment and oral steroid exposure.
• Delay also tracked with more exacerbations and less lung-function recovery.
• Consider biologics before fixed lung-function loss accumulates.

Why it matters

It challenges the reserve approach to biologics, suggesting delay itself may cost remission and lung function.

Don't overread it

This is observational; patients treated earlier may differ systematically, so it supports rethinking timing rather than proving that earlier treatment causes remission.

The statistics, in plain English

Odds ratios below 1.0 for remission with longer delay (for example 0.24 per 10 units of lung-function impairment) indicate worse outcomes the longer biologics wait, but registry data cannot fully separate delay from disease severity.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.